Spyre Therapeutics, Inc.
NASDAQ:SYREBiotechnology
+$1.21 today
- Market cap
- $9.64B
- Beta
- 3.06
- P/E (TTM)
- -171.1
- EPS (TTM)
- -$0.52
Volume 1.37M
Average 1.17M
SYRE Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Spyre Therapeutics, Inc.NASDAQ: SYRE
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development growth accelerates
Q3 FY2026 research & development of $89.17M rose 97.1% year over year, ahead of the +46.3% change in trailing-twelve-month research & development. Sequentially, it rose 36.1% from the prior quarter. Over 3 fiscal years it compounded at +43.1% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +97.1% holds above the trailing-twelve-month pace of +46.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 171.65M USD
- Year-over-year change
- +5.4%
- 4-year CAGR
- +31.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 171.65M | +5.4% |
| FY2024 | 2024-12-31 | 162.79M | +81.9% |
| FY2023 | 2023-12-31 | 89.5M | +52.8% |
| FY2022 | 2022-12-31 | 58.58M | +2.6% |
| FY2021 | 2021-12-31 | 57.07M | — |
Research & Development vs competitors
How SYRE compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +46.3% is the 4th highest of 9, against a peer median of +27.6%.
- Research & development amounts to 287.0% of revenue for SYRE, versus a peer median of 677.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $259.72M USD | +46.3% | +43.1% | 287.0% | |
| FY2025 | €177.76M EUR | +21.3% | +54.4% | — | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $147.57M USD | +91.5% | +94.3% | 4442.3% |
| LTM Mar 2026 | $128.65M USD | -23.4% | +15.3% | 55.4% | |
| LTM Mar 2026 | $86.08M USD | +3.9% | +4.8% | — | |
| LTM Mar 2026 | $74.32M USD | +33.9% | +24.8% | 17.4% | |
| LTM Mar 2026 | $56.72M USD | +60.6% | -12.2% | 677.9% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | €39.31M EUR | +49.4% | — | — |
| LTM Mar 2026 | €22.87M EUR | -34.8% | -11.8% | 77989.1% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding SYRE) | — | +27.6% | +15.3% | 677.9% | |
Competitors are the stored peer set for SYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 18.74M | 2.33M | 886K | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 171.65M |
| Gross Profit | 18.74M | 2.33M | 886K | 0 | (171.65M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| Research & Development | 57.07M | 58.58M | 89.5M | 162.79M | 171.65M |
| Selling, General & Admin | 27.32M | 28.53M | 39.95M | 45.78M | 47.91M |
| Operating Expenses | 84.39M | 87.11M | 243.19M | 208.57M | 37.91M |
| Depreciation & Amortization | 1.58M | 1.96M | 744K | 0 | 10M |
| EBITDA | (64.08M) | (81.99M) | (127.82M) | (207.97M) | (209.56M) |
| EBITDA Margin | -342.0% | -3520.3% | -14426.6% | — | — |
| Operating Income | (65.65M) | (84.78M) | (242.3M) | (208.57M) | (209.56M) |
| Operating Margin | -350.3% | -3640.2% | -27348.0% | — | — |
| Interest Income | 111K | 837K | 6.15M | 21.31M | 24.89M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (11K) | 830K | (96.51M) | 599K | 54.34M |
| Income Before Tax | (65.66M) | (83.95M) | (338.82M) | (207.97M) | (155.22M) |
| Pre-Tax Margin | -350.4% | -3604.6% | -38241.1% | — | — |
| Income Tax Expense | 141K | (136K) | (26K) | 51K | (15K) |
| Net Income | (65.8M) | (83.82M) | (338.79M) | (208.02M) | (155.2M) |
| Net Margin | -351.1% | -3598.8% | -38238.1% | — | — |
| EPS (Basic) | (25.02) | (24.86) | (46.15) | (3.18) | (1.98) |
| EPS (Diluted) | (25.02) | (24.86) | (46.15) | (3.18) | (1.98) |
| Weighted Avg Shares | 2.63M | 3.37M | 6.9M | 47.03M | 64.06M |
| Weighted Avg Shares (Diluted) | 2.63M | 3.37M | 6.9M | 47.03M | 64.06M |
Spyre Therapeutics, Inc.
NASDAQ:SYRE
Intrinsic Alpha fair value
Locked
Current Price
$101.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.